boost ilaprazol sale portfolio
optim
solid growth reiter buy tp
livzon pharma livzon report august revenu
yoy np yoy np growth
core np deduct govern grant interest incom deliv
yoy growth line expect yoy consid ilaprazol
acceler sale shenqi/ngf narrow sale declin slightli rais
ep previou
new share base nudg tp previou
base peer-averag pe reiter buy
ilaprazol fuel assist reproduct remain robust
chemic segment achiev sale yoy
anticip sale maintain momentum given digest sector
sale grew prompt ilaprazol sale growth
inject quickli expand hospit coverag expect combin sale
momentum may acceler inject put
nrdl assist reproduct deliv yoy sale growth
expect leuprorelin follicle-stimul hormon
achiev sale growth boost year pig
second line product eg rabeprazol may present growth
shenqi deliv moder declin api enjoy improv gm
shenqi realiz sale yoy predict
sale drop given lower revenu contribut
acceler grassroot penetr ngf sale declin
anticip single-digit declin api sale grew
yoy predict improv gm increas
given lift proport high margin varieti in-vitro diagnost may fuel
given new molecular diagnost launch
innov pipelin boost futur valuat
livzon rel low valuat pe close price
august believ justifi robust growth
rigid demand product limit risk gpo polici expect futur lift
valuat boost innov pipelin via hous
rhcg may approv readi phase ib trial adjuv
treatment breast cancer phase readi phase
huatai financi hold hong kong limit abbrevi huatai hk throughout report
pleas refer end page analyst certif requir disclosur
perform key product
shenqi ngf see lower sale contribut
livzon overview consist evalu process
market share
advanc statu consist
livzon huashan
financi forecast valuat
adjust key assumpt
net profit attribut
clinic trial phase antibodychem preparationtcmhighli -purifi menotrophinphas iilaunch livzon pharma hk
note cspc use ep estim huatai healthcar
livzon gm segment
api intermedi
diagnost reagent equip
livzon margin sg
sell distribut expens
asset liabil ratio rh
flow oper activ
flow invest
flow financ activ
cash equival end period
valuat methodolog risk statement
livzon pharma livzon report revenu yoy net
profit yoy np growth core net profit
deduct govern grant interest incom deliv growth line
expect yoy consid
ilaprazol acceler sale
shenqi/ngf narrow sale declin slightli rais ep
previou new share base
lift tp previou base peer-averag pe
downsid risk declin sale shenqi fuzheng given prescript
restrict adjuv drug sluggish sale chemic drug given tighter
medic insur budget gener delay new launch process
tnf-antibodi microspher product
view express report accur reflect person view analyst subject secur suer part
compens analyst directli indirectli relat inclus pecif recommend view
